Literature DB >> 35016208

European Society of Cardiology: cardiovascular disease statistics 2021.

Adam Timmis1, Panos Vardas2,3, Nick Townsend4, Aleksandra Torbica5, Hugo Katus6, Delphine De Smedt7, Chris P Gale8, Aldo P Maggioni9, Steffen E Petersen1, Radu Huculeci3, Dzianis Kazakiewicz3, Victor de Benito Rubio3, Barbara Ignatiuk10, Zahra Raisi-Estabragh1, Agnieszka Pawlak11, Efstratios Karagiannidis12, Roderick Treskes13, Dan Gaita14, John F Beltrame15, Alex McConnachie16, Isabel Bardinet17, Ian Graham18, Marcus Flather19, Perry Elliott20, Elias A Mossialos21, Franz Weidinger22, Stephan Achenbach23.   

Abstract

AIMS: This report from the European Society of Cardiology (ESC) Atlas Project updates and expands upon the widely cited 2019 report in presenting cardiovascular disease (CVD) statistics for the 57 ESC member countries. METHODS AND
RESULTS: Statistics pertaining to 2019, or the latest available year, are presented. Data sources include the World Health Organization, the Institute for Health Metrics and Evaluation, the World Bank, and novel ESC sponsored data on human and capital infrastructure and cardiovascular healthcare delivery. New material in this report includes sociodemographic and environmental determinants of CVD, rheumatic heart disease, out-of-hospital cardiac arrest, left-sided valvular heart disease, the advocacy potential of these CVD statistics, and progress towards World Health Organization (WHO) 2025 targets for non-communicable diseases. Salient observations in this report: (i) Females born in ESC member countries in 2018 are expected to live 80.8 years and males 74.8 years. Life expectancy is longer in high income (81.6 years) compared with middle-income (74.2 years) countries. (ii) In 2018, high-income countries spent, on average, four times more on healthcare than middle-income countries. (iii) The median PM2.5 concentrations in 2019 were over twice as high in middle-income ESC member countries compared with high-income countries and exceeded the EU air quality standard in 14 countries, all middle-income. (iv) In 2016, more than one in five adults across the ESC member countries were obese with similar prevalence in high and low-income countries. The prevalence of obesity has more than doubled over the past 35 years. (v) The burden of CVD falls hardest on middle-income ESC member countries where estimated incidence rates are ∼30% higher compared with high-income countries. This is reflected in disability-adjusted life years due to CVD which are nearly four times as high in middle-income compared with high-income countries. (vi) The incidence of calcific aortic valve disease has increased seven-fold during the last 30 years, with age-standardized rates four times as high in high-income compared with middle-income countries. (vii) Although the total number of CVD deaths across all countries far exceeds the number of cancer deaths for both sexes, there are 15 ESC member countries in which cancer accounts for more deaths than CVD in males and five-member countries in which cancer accounts for more deaths than CVD in females. (viii) The under-resourced status of middle-income countries is associated with a severe procedural deficit compared with high-income countries in terms of coronary intervention, ablation procedures, device implantation, and cardiac surgical procedures.
CONCLUSION: Risk factors and unhealthy behaviours are potentially reversible, and this provides a huge opportunity to address the health inequalities across ESC member countries that are highlighted in this report. It seems clear, however, that efforts to seize this opportunity are falling short and present evidence suggests that most of the WHO NCD targets for 2025 are unlikely to be met across ESC member countries. © The European Society of Cardiology 2022. All rights reserved. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardiovascular disease; European Society of Cardiology; Health infrastructure; Morbidity; Mortality; Risk factors; Service provision; Statistics

Mesh:

Year:  2022        PMID: 35016208     DOI: 10.1093/eurheartj/ehab892

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  21 in total

Review 1.  Heart Failure After Right Ventricular Myocardial Infarction.

Authors:  Matthias P Nägele; Andreas J Flammer
Journal:  Curr Heart Fail Rep       Date:  2022-10-05

Review 2.  [Metabolic syndrome and atrial fibrillation].

Authors:  Bernd Nowak; Boris Schmidt; Shaojie Chen; Lukas Urbanek; Stefano Bordignon; David Schaack; Shota Tohoku; Julian Chun
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2022-09-21

3.  [64Cu]Cu-DOTATATE PET metrics in the investigation of atherosclerotic inflammation in humans.

Authors:  Jacob K Jensen; Johanne S Madsen; Malte E K Jensen; Andreas Kjaer; Rasmus S Ripa
Journal:  J Nucl Cardiol       Date:  2022-08-31       Impact factor: 3.872

Review 4.  Heart Failure-Do We Need New Drugs or Have Them Already? A Case of Coenzyme Q10.

Authors:  Krzysztof J Filipiak; Stanisław Surma; Monika Romańczyk; Bogusław Okopień
Journal:  J Cardiovasc Dev Dis       Date:  2022-05-16

Review 5.  Extracellular Vesicles as Drivers of Immunoinflammation in Atherothrombosis.

Authors:  Rosa Suades; Maria Francesca Greco; Teresa Padró; Lina Badimon
Journal:  Cells       Date:  2022-06-05       Impact factor: 7.666

6.  Epidemiology, management, and outcomes of atrial fibrillation among 30 million citizens in Shanghai, China from 2015 to 2020: A medical insurance database study.

Authors:  Mu Chen; Cheng Li; Peng Liao; Xin Cui; Wenqi Tian; Qunshan Wang; Jian Sun; Mei Yang; Li Luo; Hong Wu; Yi-Gang Li
Journal:  Lancet Reg Health West Pac       Date:  2022-05-03

7.  The spoils of war and the long-term spoiling of health conditions of entire nations.

Authors:  Eliano P Navarese; Klaudyna Grzelakowska; Francesco Mangini; Jacek Kubica; Maciej Banach; Marianne Benn; Christoph J Binder; Jan Borén; Alberico Catapano; Florian Kronenberg; Ziad Mallat; Philippe Moulin; Katariina Öörni; Kausik K Ray; Jeanine E Roeters van Lennep; Stefano Romeo; Lale Tokgozoglu; Arnold von Eckardstein; Alberto Zambon; Paolo Raggi
Journal:  Atherosclerosis       Date:  2022-05-21       Impact factor: 6.847

8.  Clinical characteristics, outcomes and regional variations of acquired valvular heart disease patients undergoing cardiac surgery in China.

Authors:  Hongyuan Lin; Jianfeng Hou; Jiamiao Gong; Yongjian Wu; Zhe Zheng
Journal:  BMC Cardiovasc Disord       Date:  2022-04-21       Impact factor: 2.174

Review 9.  COVID-19 and kidney disease: insights from epidemiology to inform clinical practice.

Authors:  Viyaasan Mahalingasivam; Guobin Su; Masao Iwagami; Mogamat Razeen Davids; James B Wetmore; Dorothea Nitsch
Journal:  Nat Rev Nephrol       Date:  2022-04-13       Impact factor: 42.439

10.  Pharmacologic modulation of intracellular Na+ concentration with ranolazine impacts inflammatory response in humans and mice.

Authors:  Max Lenz; Manuel Salzmann; Cosmin I Ciotu; Christoph Kaun; Konstantin A Krychtiuk; Andreja Rehberger Likozar; Miran Sebestjen; Laura Goederle; Sabine Rauscher; Zoriza Krivaja; Christoph J Binder; Kurt Huber; Christian Hengstenberg; Bruno K Podesser; Michael J M Fischer; Johann Wojta; Philipp J Hohensinner; Walter S Speidl
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-13       Impact factor: 12.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.